C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 25.05 PLN 0.2% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Celon Pharma SA?
Write Note

Celon Pharma SA
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celon Pharma SA
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
C
Celon Pharma SA
WSE:CLN
Gross Profit
zł147m
CAGR 3-Years
4%
CAGR 5-Years
15%
CAGR 10-Years
N/A
M
Molecure SA
WSE:MOC
Gross Profit
-zł337.1k
CAGR 3-Years
N/A
CAGR 5-Years
-18%
CAGR 10-Years
N/A
C
Cannabis Poland SA
WSE:CBD
Gross Profit
-zł49.8k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Celon Pharma SA
Glance View

Market Cap
1.3B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
9.71 PLN
Overvaluation 61%
Intrinsic Value
Price
C

See Also

What is Celon Pharma SA's Gross Profit?
Gross Profit
147m PLN

Based on the financial report for Jun 30, 2024, Celon Pharma SA's Gross Profit amounts to 147m PLN.

What is Celon Pharma SA's Gross Profit growth rate?
Gross Profit CAGR 5Y
15%

Over the last year, the Gross Profit growth was 2%. The average annual Gross Profit growth rates for Celon Pharma SA have been 4% over the past three years , 15% over the past five years .

Back to Top